With 0.53 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.76 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.93 whereas the lowest price it dropped to was $3.75. The 52-week range on MREO shows that it touched its highest point at $5.02 and its lowest point at $1.95 during that stretch. It currently has a 1-year price target of $7.17. Beta for the stock currently stands at 0.91.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MREO was up-trending over the past week, with a rise of 8.73%, but this was down by -9.39% over a month. Three-month performance dropped to -17.17% while six-month performance rose 9.66%. The stock gained 87.38% in the past year, while it has gained 67.10% so far this year. For the next quarter, that number is 0.01. This implies an EPS growth rate of -4.17% for this year and 16.00% for next year.
Float and Shares Shorts:
At present, 154.73 million MREO shares are outstanding with a float of 137.28 million shares on hand for trading. On 2024-11-29, short shares totaled 6.63 million, which was 427.00000000000006 higher than short shares on 1730332800. In addition to Dr. Denise Vera Scots-Knight Ph.D. as the firm’s Co-Founder, CEO & Executive Director, Mr. Charles Edward Sermon serves as its Co-Founder, General Counsel, Business Development & Company Secretary.
Institutional Ownership:
Through their ownership of 0.7058 of MREO’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, MREO reported revenue of $0.0 and operating income of -$9147000.0. The EBITDA in the recently reported quarter was -$7882000.0 and diluted EPS was -$0.1.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MREO since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With MREO analysts setting a high price target of 7.992511 and a low target of 6.0080757, the average target price over the next 12 months is 7.1505904. Based on these targets, MREO could surge 107.06% to reach the target high and rise by 55.65% to reach the target low. Reaching the average price target will result in a growth of 85.25% from current levels.
Analysts have provided yearly estimates in a range of -$0.03284269 being high and -$0.03284269 being low. For MREO, this leads to a yearly average estimate of -$0.03284269. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is -$0.02. The average estimate for the next quarter is thus -$0.01.
